to realize national health security against global infectious diseases
NIID is strengthening research competency for emerging and variant infectious diseases through cooperation between national research institutes of Korea and US.
Having jointly developed a neutralizing antibody treatment for COVID-19 (Regdanvimab), NIID is continuously promoting R&D of therapeutic antibodies for infectious diseases.
Having jointly developed a neutralizing antibody treatment for COVID-19 (Regdanvimab), NIID is continuously promoting R&D of therapeutic antibodies for infectious diseases.
The department of Antimicrobial Resistance Research affiliated with NIID has been designated as a WHO Collaborating Center named "WHO Collaborating Centre for AMR Reference and One Health Research" in 2021 and contributes to the surveillance and overcoming of antimicrobial resistance.
NIID is conducting a joint international study to develop a candidate for the SFTS mRNA vaccine.
NIID is conducting a joint international study to develop a candidate for the SFTS mRNA vaccine.